Biomark Diagnostics Inc. (FRA:20B)

Revenue by Segment

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Develop, an Advanced Stage Cancer Diagnostic Business	154.22K	163.22K	153.49K	43.93K		263.28K
Develop, an Advanced Stage Cancer Diagnostic Business Growth	-5.52%	6.34%	249.38%	-		-
Total	154.22K	163.22K	153.49K	43.93K		263.28K
Total Growth	-5.52%	6.34%	249.38%	-		-

Revenue by Geography

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Canada	154.22K	163.22K	153.49K	43.93K		263.28K
Canada Growth	-5.52%	6.34%	249.38%	-		-
Total	154.22K	163.22K	153.49K	43.93K		263.28K
Total Growth	-5.52%	6.34%	249.38%	-		-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 11, 2026

Data Sources Report a data error